Cel Sci CORP

CEL-SCI Corporation's annual shareholder meeting on August 14, 2026, resulted in the election of directors and approval of stock incentive plans, with routine ratification of auditors.

CEL-SCI Corporation has successfully closed a best-efforts offering of 2,500,000 shares of common stock at $1.00 per share, raising $2.5 million in gross proceeds.

CEL-SCI Corporation has entered a strategic distribution and revenue-sharing agreement with Saudi Amarox Co. to commercialize its immunotherapy candidate, Multikine, in Saudi Arabia.

CEL-SCI Corporation announced the pricing of a public offering of 6,000,000 shares of common stock at $1.20 per share, raising approximately $7.2 million in gross proceeds.

CEL-SCI Corporation's Board of Directors has adopted a Shareholder Rights Agreement, commonly known as a 'poison pill,' to protect against coercive takeover attempts and ensure fair value for shareholders.

CEL-SCI Corporation has amended its Shareholder Rights Agreement, extending its expiration date to October 30, 2030, a move designed to protect against hostile takeovers.

CEL-SCI Corporation's Q3 2026 10-Q filing reveals significant net losses and substantial doubt about its ability to continue as a going concern, despite promising clinical data for its lead drug candidate, Multikine.

CEL-SCI Corporation reported a reduced net loss for the nine months ended June 30, 2025, while advancing its Multikine immunotherapy toward a confirmatory registration study despite ongoing liquidity concerns.

CEL-SCI Corporation reports its financial results for the quarter ended March 31, 2025, highlighting its focus on advancing Multikine through a confirmatory registration study.

CEL-SCI Corporation reports its financial results for the quarter ended December 31, 2024, and provides an update on its clinical development program for Multikine.

CEL-SCI Corporation reported its financial results for the third quarter of 2024 and provided an update on its lead investigational therapy, Multikine, including plans for a confirmatory registration study.

CEL-SCI Corporation reported its financial results for the quarter ended March 31, 2024, and provided an update on its regulatory strategy for Multikine.

CEL-SCI Corporation's latest 10-K filing highlights positive Phase III Multikine data for head and neck cancer, outlining plans for a confirmatory study while facing ongoing financial losses and a going concern doubt.

CEL-SCI Corporation announces its fiscal year 2024 results, highlighting progress towards a confirmatory study for Multikine in head and neck cancer treatment.

Robert Eugene Watson, a Director of Cel Sci Corp, received 110,000 shares of common stock on August 14, 2026.

Bruno Jean-Marie Baillavoine, a Director of Cel Sci Corp, received 110,000 shares of common stock on August 14, 2026.

John Cipriano, Senior Vice President of Cel Sci Corp, received 80,000 shares of common stock on August 14, 2026.

Eyal Talor, Chief Scientific Officer of Cel Sci Corp, received 250,000 shares of common stock on August 14, 2026.

Patricia B Prichep, Chief Financial Officer of Cel Sci Corp, received 225,000 shares of common stock on August 14, 2026.

Geert R Kersten, Chief Executive Officer and a Director of Cel Sci Corp, received 300,000 shares of common stock on August 14, 2026.

CEL-SCI Corporation has issued a Notice of Annual Meeting of Shareholders to be held on August 14, 2026, detailing proposals including director elections, stock plan approvals, executive compensation votes, and auditor ratification.

CEL-SCI Corporation is holding its annual shareholder meeting on May 19, 2025, to vote on key proposals including the election of directors, adoption of new stock option and bonus plans, a potential reverse stock split, and ratification of the company's auditor.

CEL-SCI has identified a target patient population for its Multikine cancer therapy and is advancing regulatory filings after overcoming manufacturing challenges.

CEL-SCI Corporation announces its annual shareholder meeting to be held on April 19, 2024, including proposals to elect directors, adopt a new stock option plan, and ratify the appointment of its independent accounting firm.

CEL-SCI Corporation has filed an amendment to its registration statement to raise approximately $13.7 million through a best-efforts offering of common stock and pre-funded warrants.

CEL-SCI Corporation has filed a registration statement for a best-efforts offering of up to 3,440,367 shares of common stock and pre-funded warrants to raise approximately $13.7 million in net proceeds.

Lincoln Alternative Strategies LLC has reported a 6.94% beneficial ownership stake in CEL-SCI Corporation, holding 555,000 shares of common stock.